MedPath

Opus Genetics, Inc.

Opus Genetics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2004-01-01
Employees
11
Market Cap
-
Website
http://opusgtx.com

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (50.0%)
Phase 1
1 (50.0%)

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Not Applicable
Recruiting
Conditions
ARB
BVMD
Autosomal-Dominant Bestrophinopathy
Best Vitelliform Macular Dystrophy
First Posted Date
2025-09-22
Last Posted Date
2025-09-30
Lead Sponsor
Opus Genetics, Inc
Target Recruit Count
10
Registration Number
NCT07185256
Locations
🇺🇸

Retina Foundation of the Southwest, Dallas, Texas, United States

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)

Phase 1
Recruiting
Conditions
LCA5
Interventions
First Posted Date
2022-11-15
Last Posted Date
2025-06-12
Lead Sponsor
Opus Genetics, Inc
Target Recruit Count
15
Registration Number
NCT05616793
Locations
🇺🇸

University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.